BNP PARIBAS ASSET MANAGEMENT Holding S.A. Has $200.95 Million Stock Holdings in Hologic, Inc. (NASDAQ:HOLX)

BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 8.6% during the 3rd quarter, Holdings Channel reports. The firm owned 2,466,888 shares of the medical equipment provider’s stock after purchasing an additional 195,285 shares during the quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A.’s holdings in Hologic were worth $200,952,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently modified their holdings of the company. Pzena Investment Management LLC acquired a new position in shares of Hologic during the 3rd quarter worth about $247,000. First Horizon Advisors Inc. increased its stake in shares of Hologic by 38.3% during the 3rd quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock worth $39,000 after purchasing an additional 134 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of Hologic during the 3rd quarter worth about $2,350,000. PNC Financial Services Group Inc. boosted its holdings in shares of Hologic by 13.8% during the 3rd quarter. PNC Financial Services Group Inc. now owns 37,161 shares of the medical equipment provider’s stock worth $3,027,000 after buying an additional 4,504 shares during the period. Finally, B. Metzler seel. Sohn & Co. Holding AG bought a new stake in shares of Hologic during the 3rd quarter worth about $3,164,000. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Hologic Stock Performance

NASDAQ HOLX opened at $78.04 on Thursday. The firm has a 50-day moving average price of $80.52 and a two-hundred day moving average price of $78.30. Hologic, Inc. has a 12-month low of $67.59 and a 12-month high of $84.67. The company has a quick ratio of 3.03, a current ratio of 3.69 and a debt-to-equity ratio of 0.49. The company has a market capitalization of $18.13 billion, a P/E ratio of 23.44, a P/E/G ratio of 2.48 and a beta of 0.98.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.01. Hologic had a net margin of 19.59% and a return on equity of 19.79%. The company had revenue of $987.90 million during the quarter, compared to the consensus estimate of $978.25 million. During the same quarter in the prior year, the firm posted $0.89 EPS. The firm’s quarterly revenue was up 4.5% on a year-over-year basis. Analysts anticipate that Hologic, Inc. will post 4.27 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts recently commented on the stock. StockNews.com raised shares of Hologic from a “hold” rating to a “buy” rating in a report on Thursday, November 14th. UBS Group lifted their target price on shares of Hologic from $84.00 to $90.00 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. Raymond James lifted their target price on shares of Hologic from $93.00 to $95.00 and gave the stock an “outperform” rating in a report on Tuesday, November 5th. Needham & Company LLC reaffirmed a “buy” rating and set a $90.00 target price on shares of Hologic in a report on Tuesday, October 15th. Finally, Leerink Partners reduced their target price on shares of Hologic from $95.00 to $90.00 and set an “outperform” rating for the company in a report on Tuesday, October 8th. Four equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat.com, Hologic currently has an average rating of “Moderate Buy” and an average price target of $89.91.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.